The agreement has been signed by Sanofi-aventis with the laboratory of Gerard Karsenty to evaluate the role of osteocalcin, osteoblast-secreted peptide in diabetes management.
As per the agreement, Sanofi-aventis will sponsor research in Karsenty’s laboratory and has an option to license and develop existing patents and results that may arise from the research into potential diabetes treatments.
Sanofi-aventis US senior vice president Paul Chew said the company strives to deliver innovative and integrated patient-focused solutions for people living with diabetes, and this collaboration with Columbia University is an opportunity to collaborate with leading scientists on a new approach to diabetes management.